Rpg Life Sciences Limited · NSE:RPGLIFE
Rpg Life Sciences — Investor Presentation (November 2017)
22 slides from Rpg Life Sciences's investor presentation, Nov 15, 2017
Slide 1: RPG Life Sciences
RPG LIFE SCIENCES November 15, 2017 To, The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai - 400 051. Symbol: RPGLIFE Dear Sir/Madam, RPG LIFE SCIENCES LIMITED Unit No. 208-213, B Win
Slide 2: Investor Presentation
Investor Presentation November 15, 2017
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: Table of Contents
Table of Contents Company Overview FY 17 Performance Highlights Strategic Direction Financial Figures 3
Slide 5: Business Overview
Business Overview ▪ Mostly APIs for captive use ▪ TGA approved unit in Thane ▪ Revenue: Rs 43 crs API Revenue : Rs 298 crs PBT : Rs 15.3 crs 2 Production Units Exports : 33% ~1150 Employees Domestic International API Formulations Formulations ▪ EUGMP approved unit in ▪ Field force of 500 people ▪ St
Slide 6: Management Team
Management Team CT Renganathan BM Sundaram Satessh Singh Dr Nitin Gore Mahesh Narayanaswamy Managing Director API, Int'l Form & Main Division, Neolife, Chief Quality Officer Finance, IT Nephrocare Urolife, Glodiance Himmat Patel Kartick Patra Suchitra Tiwari Tushar Joshi Formulation Mfg API Manufact
Slide 7: Board of Directors
Board of Directors Name Experience Harsh Vardhan Goenka – Chairman Chairman, RPG Group CT Renganathan - Managing Director Ex-GSK India, Boston Scientific and Eli Lilly Sachin Nandgaonkar - Non Executive Director Ex-Senior Partner at BCG CL Jain – Independent Director Ex-CFO at Hoechst India Dr Lalit
Slide 8: Manufacturing Facilities
Manufacturing Facilities Ankleshwar, Unit 1 Ankleshwar, Unit 2 • Formulations Plant • Formulations Plant • WHO approved • WHO/EUGMP approved Navi Mumbai • API Plant • WHO/EUGMP/TGA approved 7
Slide 9: FY 16-17: Second consecutive year of good results
FY 16-17: Second consecutive year of good results Rs crs FY 14-15 FY 15-16 FY 16-17 Results Results Results Growth Sales 210 251 292 16% PBT (2.02) 8.4 13.8 64% PBT % (1%) 3.3% 4.7% +140 bps EPS 0.60 7 12 76% Share Price 63-123 140-342 240-449 31% Market Cap 104-203 232-566 400-741 31% Note : Sales,
Slide 10: FY 16-17: Key Updates (1/2)
FY 16-17 : Key Updates (1/2) Business portfolio streamlining ▪ Biotech business divested ▪ 7 brands acquired from Sun Pharma to strengthen Domestic Formulation business ▪ Urology division launched; brands from Sun and additional products ▪ Strong focus on International formulations; growth of 39% Im
Slide 11: FY 16-17: Key Updates (2/2)
FY 16-17 : Key Updates (2/2) Further strengthening of India Formulations business ▪ Continue to perform above industry growth ▪ PCPM improvement to 3.88 lakhs vs 3.59 lakhs last year ▪ EBIDTA improvement to 15.8 crs vs 12.4 crs last year ▪ Romilast & Sildura (brands acquired from Sun) gaining moment
Slide 12: India Formulations: Fundamentals getting stronger
India Formulations : Fundamentals getting stronger ₹ cr Sales ₹ lakhs PCPM 200 3.9 4.0 168 183 4.0 3.6 3.5 150 143 2.8 3.0 105 100 92 2.0 50 1.0 - 0.0 FY15 FY16 FY17 H1 FY17 H1 FY18 FY15 FY16 FY17 H 1'17 H 1'18 New Product % DPCO sales % 24% 38% 25% 40% 20% 34% 35% 20% 16% 30% 25% 24% 15% 9% 20% 10%
Slide 13: Main Division: Strong consolidation continues
Main Division : Strong consolidation continues Rs. Crs FY 14-15 FY 15-16 FY 16-17 YOY% H1 FY 18 Sales 86.30 104.5 121.3 +16% 72.1 Gross Margin 41.1 54.9 67.9 +24% 40.1 as % to Sales 48% 53% 56% +300 bps 55% EBIDTA -5.7 3.2 13.8 +331% 9.4 as % to Sales -7% 3% 11% +800 bps 13% PBT -7.5 1.7 10.6 +523%
Slide 14: Key Brand Sales Main Division
Main Division Key Brand Sales Rs. 14 13.56 13.16 12 10.52 10.52 10 8.98 9.45 8.11 8 7.22 6.85 6.74 6.13 5.79 5.76 6 5.05 4.01 4 2 0 Lomotil Aldactone Naprosyn Tricaine Minmin Tonic H1 FY 16 6.85 9.45 5.79 5.76 4.01 H1 FY 17 8.98 10.52 8.11 5.05 6.74 H1 FY 18 13.56 13.16 10.52 7.22 6.13
Slide 15: Nephro Division: Very profitable, but growth challenged
Nephro Division : Very profitable, but growth challenged Rs. Crs FY 15 FY 16 FY 17 YOY% H1 FY 18 Sales 41.1 47.6 43.6 -8% 22.7 Gross Margin 25.2 27.3 25.5 -7% 13.1 as % to Sales 61% 57% 58% +100 bps 56% EBIDTA 11.5 11.0 10.1 -8% 4.6 as % to Sales 28% 23% 23% - 20% PBT 10.8 10.3 9.6 -7% 4.3 as % to S
Slide 16: Other Divisions: Still early days
Other Divisions: Still early days Neolife (Oncology) • Sales at Rs 9.7 cr; lower than LY by 7%. However H1’18 sales at Rs 6.85 cr higher than corresponding LY of Rs 5.61 cr. • Declining prices due to very high competitive intensity, large proportion of institutional sales and commodity product baske
Slide 17: Int'l Formulations: Growth efforts starting to yield results
Int’l Formulations: Growth efforts starting to yield results ₹ cr ₹ cr 40 ROW Sales Regulated Market Sales 35 40 30 30 30 27 25 22 19 20 19 20 20 11 9 10 10 0 0 FY15 FY16 FY17 H1'17 H1'18 FY15 FY16 FY17 H1'17 H1'18 • Growth driven by increased orders from • 100% growth achieved existing approvals •
Slide 18: Regulated Markets: Product Portfolio
Regulated Markets: Product Portfolio Existing Products Products Under Development ▪ Azathioprine ▪ Sodium Valproate - EUCTD ▪ Mycophenolate Mofetil ▪ Aminocaproic Acid – ANDA ▪ Nicorandil – EUCTD ▪ Azathioprine – ANDA ▪ Sertraline (Contract Mfg) ▪ Solefinacin - ANDA ▪ Clotrimoxazole (Contract Mfg) 1
Slide 19: ROW: Increasing market coverage short term focus
ROW: Increasing market coverage short term focus Sales Markets under Existing Markets (FY 17 ₹ crs) development Siloxogene is one of the Myanmar 12.54 Honduras fastest growing brands in Myanmar Mauritius 9.63 Angola Egypt 6.29 Nicaragua Kenya 0.89 Sudan Product expansion through Vietnam 0.67 Ethiopi
Slide 20: Strategy: No change; continue to be on same path
Strategy: No change; continue to be on same path ▪ Focus : Captive molecules for Global Formulation ▪ Approach : Own the technology; outsource manufacturing to USFDA approved sites API Domestic ▪ Focus : Few therapy Formulations areas/ product segments ▪ Focus : Immediate term- ▪ Approach : New prod
Slide 21: Financial Figures: Q2 and H1'18
Financial Figures : Q2 and H1‘18 Rs.Cr. Parameter Q2FY17 Q1FY18 Q2FY18 QoQ YoY H1 FY17 H1 FY18 YoY Net Revenue from Operations 77.22 75.32 89.51 18.8% 15.9% 156.69 164.83 5.2% Raw Material 28.42 23.70 30.93 30.5% 8.8% 57.69 54.63 -5.3% Gross margin 48.80 51.62 58.58 13.5% 20.0% 99.00 110.20 11.3% Gr
Slide 22: Thank You
T H A N K Y O U
RPG Life Sciences — Investor Presentation (November 2017) on 6ix